Condition: Relapsed and/or Refractory Multiple Myeloma · Sponsor: OriCell Therapeutics Co., Ltd.
An open label, dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of OriCAR-017 in R/RMM
This description comes directly from the study's public registry record.
HE Huang, MD · 0571-88208277 · hehuangyu@126.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital College of Medicine Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
| Beijing GoBroad Hospital | Beijing, China | Not Yet Recruiting |
| The First Affiliated Hospital with Nanjing Medical University | Nanjing, China | Not Yet Recruiting |
| Tongji Hospital of Tongji University | Shanghai, China | Not Yet Recruiting |
| Union Hospital Tongji Medical College Huazhong University of Science and Technology | Wuhan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06182696